Visual evoked potential can be recovered by Okayama University-type retinal prosthesis (OUReP™) implantation in blind rats.
March 08(Wed), 2017
A medical-engineering joint research group consisting of Toshihiko Matsuo, Associate Professor at Department of Ophthalmology, Okayama University Medical School and Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Alamusi, part-time researcher at the department, Osamu Hosoya, Assistant Professor at Department of Medical Neurobiology at the graduate school, and Tetsuya Uchida, Associate Professor at Department of Polymer Materials Science, Okayama University Faculty of Engineering and Graduate School of Natural Science and Technology have demonstrated for the first time that the Okayama University type-retinal prosthesis OURePTM (the world’s first, novel system) recovers vision in rats, by observing visual evoked potentials. This study was reported in Journal of Artificial Organs, an English journal published from Japanese Society for Artificial Organs, on February 8.
Photoelectric dye used for Okayama University-type retinal prosthesis prevents light-sensing visual cells in rats’ eyes from death.
Shihui Liu, a Ph.D. student at Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, Associate Professor Toshihiko Matsuo, Assistant Professor Osamu Hosoya, and Associate Professor Tetsuya Uchida have announced their world first discovery that the photoelectric dye used in OURePTM has neuroprotective action to inhibit death of photoreceptor cells in rats. This study was reported in the U.S.’s scientific journal Journal of Ocular Pharmacology and Therapeutics on January 13.
OURePTM is a retinal prosthesis in a form of dye-coupled film, a world first, novel system very different from the camera image-capture and electrode-array output system put on the market in 2013 in the U.S. The group has been consulting Pharmaceuticals and Medical Devices Agency (PMDA) on their pharmaceutical strategy, and preparing for an investigator-initiated clinical trial expected to be conducted at Okayama University Hospital in compliance with Japan’s Pharmaceutical and Medical Device Act (former Pharmaceutical Affairs Act).
Since medical devices only at the level of research seeds cannot be delivered to patients, retinal prostheses for use in clinical trials are required to have absolute safety, excellent efficacy, and highly-controlled quality. This study has assured the efficacy of the retinal prosthesis, making another step closer to the investigator-initiated clinical trial, which would eventually lead to patients’ benefit.
Journal: Journal of Artificial Organs
Authors: Alamusi, Toshihiko Matsuo, Osamu Hosoya, and Tetsuya Uchida
Title: Visual evoked potential in RCS rats with Okayama University-type retinal prosthesis (OUReP™) implantation.
Year of Publication: 2017
Journal: Journal of Ocular Pharmacology and Therapeutics
Authors: Shihui Liu, Toshihiko Matsuo, Osamu Hosoya, and Tetsuya Uchida
Title: Photoelectric dye used for Okayama University-type retinal prosthesis reduces the apoptosis of photoreceptor cells.
Year of Publication: 2017
Okayama University Silicon Valley Office (OUSVO)
|Contact:||Mototaka Senda, Ph.D.|
- OURePTM, etinal prostheses